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<ABSTRACT> 
Radioiodine treatment (30 mCi) for postsurgical remnant ablation 
in patients with differentiated thyroid carcinoma: Comparative 
analysis of patient preparation using conventional thyroid hormone 
(LT4/T3) withdrawal or recombinant human TSH 
 
Department of Medicine  
The Graduate School, Yonsei University  
 
(Directed by Professor  Woong Youn Chung) 
 
Jandee Lee 
 
 
 
 
Purpose: Few reports have examined the use of recombinant human 
TSH(rhTSH) for ablation of postsurgical thyroid remnants after low dose RI 
(radioactive iodine) therapy, compared with conventional thyroid hormone 
withdrawal. The aim of the present study was to explore the effectiveness of 
each patient preparation method before RI ablation(30mCi) of the remnant 
thyroid in patients with differentiated thyroid carcinoma(DTC). 
Methods: This study included three groups of patients, enrolled consecutively. 
From February 2006 to March 2007, 291 patients were enrolled and 
randomized, after total thyroidectomy, to a 4-week LT4 withdrawal 
group(Group, I, n=89), a 2-week T3 withdrawal group(Group II, n=133), and 
a rhTSH administration group(Group III, n=69). Quality-of-life(QoL) was 
determined at the time of ablation. 
Results: Patients in the three groups did not differ significantly in baseline 
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characteristics or TNM staging. In all study groups, serum TSH levels showed 
very good stimulation(mean, 82.24±18.21 mU/L), without significant 
between-group differences(p=0.5213). Follow-up examinations performed 12 
months after ablation were satisfactory in all study patients, without 
significant between-preparation differences(p=0.2061). QoL was better 
preserved in Group III than in Groups I and II(p<0.0001). However, there was 
no QoL difference at the time of ablation between Groups I and II.  
Conclusion: Our study indicates that use of rhTSH preserves QoL in patients 
undergoing RI ablation, and affords an ablation success rate comparable to 
that seen after thyroid hormone withdrawal. However, ablation preparation 
using withdrawal of LT3 for 2 weeks did not prevent development of 
profound hypothyroidism, as also occurred when LT4 alone was withdrawn 
for 4 weeks. 
 
 
 
 
 
 
 
 
------------------------------------------------------------------------------------------------------- 
Key words : rhTSH, low dose radioiodine treatment, quality of life, T3 
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I. INTRODUCTION 
 
Initial treatment for differentiated thyroid carcinoma (DTC) is total or near-
total thyroidectomy, which is often followed by [
131
I] radioiodine (RI) 
ablation of remnant thyroid tissue after 4 weeks of LT4 (levothyroxine) 
withdrawal. Long-standing hypothyroidism has profound effects on many 
organs and systems, and causes cognitive impairment; emotional 
dysfunction; physical discomfort; and health risks in patients who are 
elderly, frail, or have concomitant illnesses. Withdrawal of thyroid hormone 
may also have a profound negative impact on patient quality-of-life (QoL) 
and ability to work in healthy young subjects 
1-3
.  
The standard protocol of RI ablation involves withdrawal of thyroid 
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hormone to stimulate endogenous TSH, thereby inducing long-standing 
hypothyroidism. In the current protocol, remnant ablation after thyroid 
hormone withdrawal promotes RI uptake in residual thyroid cells. The 
consensus of the European Thyroid association and the guidelines of the 
American Thyroid Association for patients undergoing RI therapy or 
diagnostic scanning is that LT4 can be withdrawn for at least 3 weeks, or, 
alternatively, LT3 (Cytomel® ; Theramed, Mississauga, Canada) can be 
administered for 2 weeks followed by LT3 withdrawal for 2 weeks 
4,5
. 
In recent years, the development of more effective DTC treatment and the 
introduction of new follow-up modalities have led to modifications in 
patient management in order to improve QoL. Recombinant human TSH 
(rhTSH; TSHα; Thyrogen; Genzyme Corp., Cambridge, MA) has become 
available. The use of rhTSH has been invaluable in DTC management. 
Hypothyroidism is now avoidable at the time of RI ablation. The use of 
rhTSH permits maintenance of good QoL 
3,4.6
, without side-effects, and 
requires only minor whole-body irradiation 
7-9
. rhTSH use has been 
approved by the European Medicine Agency (EMEA) and the United States 
Food and Drug Administration (FDA) for DTC patients treated with 3.7 
GBq (100 mCi) RI. However, a postoperative low-dose (30 mCi) RI 
ablation of remnant thyroid tissue, after rhTSH patient preparation, remains 
controversial. To date, only four prospective studies have explored the 
efficacy of low-dose (30 mCi) RI ablation after such preparation 
10-13
, 
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because low RI doses have not been commonly used in medical centers 
11-13
.  
The present study was designed to investigate whether patient preparation 
using rhTSH was comparable to conventional methods (T4/T3 withdrawal) 
with respect to efficacy of postsurgical remnant ablation, in low-risk 
patients receiving a fixed 30 mCi RI dose. In addition, a between-method 
comparison of peri-ablation QoL was performed. 
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 II. MATERIALS AND METHODS 
 
1. Inclusion Criteria 
Patients with newly diagnosed DTC, more than 18 years old, who had 
recently undergone total or near-total thyroidectomy with central 
compartment neck dissection (CCND), were eligible for this study. 
Exclusion criteria were evidence of distant metastases (M1), lateral neck 
node metastases (N1b), and/or significant extrathyroidal invasion (T4) 
(TNM classifications) 
14
. As individually assessed by the principal 
investigator at each site, included patients had no clinically significant 
abnormalities on routine hematological or blood chemistry tests, and serum 
creatinine concentrations were normal. No patient had any major concurrent 
medical disorder, including other malignancies, within the past 5 years, and 
no patient had recently been prescribed drugs affecting thyroid or renal 
function, including iodine-containing medications or radiocontrast agents. 
The study was approved by our Institutional Review Board and written 
informed consent was obtained from each patient.  
 
2. Study design 
The study was a prospective, randomized, controlled, open-label, single 
center study. The study was designed to compare the efficacies of various 
patient preparation methods prior to postsurgical remnant ablation using 
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low-dose (30 mCi) RI, and to explore QoL in patients undergoing RI 
treatment.  
All patients underwent total thyroidectomy with CCND. After operation, all 
patients began treatment with a TSH-suppressing dose of LT4 (2ug/kg). 
After at least 30 days of LT4 supplementation, patients were randomized 
into three groups by RI preparation protocol. In Group I, patients 
discontinued LT4 for 4 weeks; in Group II, patients converted to LT3 for 2 
weeks and then discontinued LT3 for 2 weeks; and in Group III, patients 
received rhTSH with a short stoppage(4 days) of LT4 from the day before 
rhTSH until iodine administration to emphasize the interference of iodine 
content of LT4 on the effectiveness of radiometabolic treatment. 
RI treatment was performed on all patients after 2 weeks on a low-iodine 
diet. Measurements of circulating thyroid hormone, TSH, thyroglobulin 
(Tg), and anti-Tg antibodies (TgAbs) were performed at ablation, and before 
and after thyroid hormone withdrawal.  
In the rhTSH injection group, rhTSH was administered to ambulatory 
patients as two 0.9 mg IM injections on 2 consecutive days, followed by the 
RI therapeutic dose 24 hours after the last injection, and a whole body scan 
was performed 48 hours after RI treatment. Serum TSH, free T4(fT4), T3, 
Tg, and TgAbs were measured on the day before the first administration of 
rhTSH and the day after the second rhTSH administration. Serum samples 
for Tg and TgAbs assessment were taken 3 days after the second rhTSH 
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injection. Serum TSH and fT4 were measured by chemiluminescence 
immunoassay(Centaur; Bayer Health Care, Mannheim,Germany), as was T3 
(E-170 assay kit; Roche Diagnostics, Mannheim, Germany). Serum Tg was 
measured by immunoradiometric assay (Dynotest TgS, Brahms, Berline, 
Germany), as was TgAbs (Anti-Tgn RIA, Brahms, Berline, Germany). The 
Tg assay had a sensitivity of 0.2 ng/mL. TgAbs status was considered 
negative when readings were less than 20 IU/mL. Patients with potentially 
interfering levels of TgAbs were excluded from statistical analysis of serum 
Tg changes. To eliminate contamination by stable iodine, urinary iodine 
excretion over 24 hours was measured in all patients before RI 
administration and at follow-up assessment. Iodine measurements were 
performed in a central laboratory (the SCL facility of the Asan Medical 
Center; Seoul, Korea); an iodine-selective colorimetric method was 
employed.  
To measure remnant thyroid activity, a tracer dose (7.4MBq) of RI was 
given orally to all patients the day before therapeutic RI administration. 
Images were obtained 2 hours and 24 hours later using a single-head gamma 
camera (KOROID, Seyong, Korea) featuring a 3/8-inch-thick crystal and a 
pinhole collimator. Residual thyroid bed uptake was evaluated both 
qualitatively (positive or negative) and quantitatively. Post-therapy whole 
body scans (WBSs) were acquired 48 hours after RI treatment. 
 
- 9 - 
 
3. Measurement of quality- of- life 
We aimed to determine clinical QoL. We designed a seven-item written, 
anonymous questionnaire exploring hypothyroidism consequences for daily 
living during thyroid hormone withdrawal. The survey items focused on 
physical symptoms, signs, problem duration, impact on social life, mood 
changes, and medical resource utilization. Our psychometric study was a 
modified version of the self-rating Kellner Symptoms Questionnaire (KSQ), 
the Hamilton depression scale (HDS), and Luster’s 13-item scale for 
measurement of hypothyroidism 
2,15
. The minimum possible score is 0 and 
the maximum score is 31. At the time of RI ablation, our questionnaires was 
utilized, in a double-blinded fashion, to assess the hypothyroidism status of 
the patients. The same observer, blinded to the patient’s clinical state, 
administered the questionnaires at all time. Both the observer and the 
patients were blinded to the treatment group being assigned Appendix 1 
contains an English translation of the questionnaire. 
4. Assessment of ablation success 
In all patients, serum TSH, fT4, T3, Tg, and Tg Abs levels were periodically 
measured. After 12-18 months, ablation outcomes were assessed in each 
group by follow-up WBS, serum Tg measurement after TSH stimulation, 
and neck ultrasonography (US). To image thyroid remnants, a tracer dose of 
150 MBq RI was administered to all patients. Neck US was performed by a 
radiologist specializing in head-and-neck evaluation using a Philips-ATL 
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HDI 5000 instrument equipped with a 12 MHz linear transducer.  
 
5. Statistical anlaysis.   
All data were expressed as means ± standard deviations (SDs), proportions, 
or absolute numbers. The Mann-Whitney U test and Kruskal-Wallis 
assessment were used to analyze between-group differences, and the 
Wilcoxon rank sum test was used for paired analysis within a group. The t-
test was employed to explore the significance of differences between 
unpaired data. The χ2 test was used to compare between-group clinical and 
pathological features. A p value <0.05 was considered significant. SPSS for 
Windows version 12.0 (SPSS Inc., Chicago, IL) was used for all analyses.  
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 III. RESULTS 
 
1. Patient characteristics  
Between February 2006 and March 2007, 291 patients were randomized, 
after total thyroidectomy, to conventional 4-week withdrawal of T4 (Group 
I, n=89), 2-week withdrawal of T3 (Group II, n=133), and rhTSH injection 
(Group III, n=69). The three groups did not differ in clinical characteristics 
or TNM classifications. Urinary iodine concentration before RI ablation was 
not significantly different between groups. <Table1>. 
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Table 1. Epidemiological and clinical characteristics of study patients. 
 
  Group I  Group II  Group III      p-value 
Age (years)   
50.1±6.8  49.0±10.2 46.7±9.8       0.2151 
Gender (female/male)   
83/6  118/15  64/5       0.1583 
Body mass index (kg/m
2
)  
23.4±4.68 21.9±5.63 22.8±5.41     0.2572 
Papillary/follicular carcinoma  
88/1  131/2  68/1       0.8551 
TNM staging 
T1  48 (53.9%) 61 (45.9%) 28 (40.6%) 
T2  2 (2.2%)  12 (9.0.0%) 1 (1.4%) 
T3  39 (43.9%) 60 (45.1%) 40 (58.0%)     0.7541 
N0  51 (57.3%) 78 (58.6%) 45 (65.2%) 
N1a  38 (42.7%) 55 (41.4%) 24 (34.8%)     0.1425 
Urinary iodine concentration(ug/dL, 24hrs) 
  12.3±8.3  17.6±12.5 13.8±6.1      0.5214 
 
 
2. Stimulated serum TSH and RI uptake 
As shown in Fig. 1, serum TSH was elevated in Group I (mean, 81.2±19.0 
mU/L; range, 33.1~100.0 mU/L), Group II (mean, 73.6±19.4 mU/L; range, 
30.1~100.0), and Group III (mean, 86.6±17.6 mU/L; range 33.1~100.0 
mU/L), without significant between-group differences (p=0.5213). <Fig.1>  
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Fig. 1. Stimulated serum TSH levels in the three Groups after preparation. 
 
 
The basal 2-hour and 24-hour thyroid bed uptakes (% values) after 
administration of tracer RI were 1.9±1.1% (range, 0.2~10.7%) and 2.2±1.4% 
(range ,0.1~9.8%) in Group I; 2.0±1.9% (range, 0.2~10.7%), and 3.1±2.5% 
(range, 0.2~19.5%) in Group II; and 2.1±3.0% (range, 0.1~10.1%) and 
1.8±1.6% (range, 0.1~13.4%) in Group III. Thyroid bed RI uptake after 2 
hours showed no statistically significant between-group difference. Thyroid 
RI uptake after 24 hours tended to be lower in Group III than in Groups I or 
II, although the differences were not statistically significant (p=0.3684 vs. 
0.0952, respectively). <Fig.2>  
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Fig. 2. Two-hour and 24-hour thyroid bed uptakes in each Groups. 
 
 
 
3. Serum Tg response to TSH stimulation  
At the time of RI ablation, mean serum TSH was comparable in the three 
groups. Serum Tg level was 0.95±1.16 ng/mL (range, 0.1~4.7 ng/mL) in 
Group I, 1.12±1.22 ng/mL (range, 0.1~5.1 ng/mL) in Group II, and 
0.95±1.63 ng/mL (range, 0.1~9.0 ng/mL) in Group III, with no significant 
between-group differences (p=0.1084). Three days after RI ablation, serum 
Tg was 2.30±2.46 ng/mL (range, 0.2~13.3 ng/mL) in Group I, 2.72±2.45 
ng/mL (range, 0.1~10.4 ng/mL) in Group II, and 2.53±2.92 ng/mL (range, 
0.1~11.1 ng/mL) in Group III, again with no statistically significant 
between-group differences (p=0.2015). After 12-18 months of follow-up, 
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mean serum Tg levels after TSH stimulation were 0.18±0.14 ng/mL (range, 
0.1~2.9 ng/mL) in Group I, 0.14±0.19 ng/mL (range, 0.1~3.2 ng/mL) in 
Group II, and 0.14±0.05 ng/mL (range, 0.1~0.2 ng/mL) in Group III, once 
again with no significant differences between groups (p=0.1094). <Fig. 3> 
 
Fig. 3. Serum Tg levels in the three Groups at ablation, 2 days after ablation, 
and 12 months after ablation.  
 
 
4. Ablation outcomes (correlation between neck RI scans, stimulated Tg 
levels, and neck US data) 
To assess the effectiveness of each preparation method, each patient 
underwent a WBS using a tracer RI dose, and neck US, 12-18 months after 
ablation. Stimulated Tg measurement after 4-week LT4 withdrawal was 
scheduled for each patient. The successful ablation rates are shown in Table 
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2. When correlating ablation outcomes with patient preparation methods 
before RI ablation, we found that rhTSH injection offered an ablation 
success rate equivalent to that achieved by thyroid hormone withdrawal. 
 
Table 2. Ablation success rate 12 months after RI treatment. 
 
    Group I Group II        Group III    p-value 
No visle uptake  
or uptake<0.1%   
with US- negative    84/89  125/133  63/69 
(94.4%) (94.0%)  (91.3%)  
  
Serum Tg    81/89  122/133  64/69 
≤1.0ng/mL    (91.0%) (91.7%)  (92.7%) 
 
Total ablation  
success rate (%)    91.0% 91.7%  91.3%      0.2061 
 
 
5. Quality- of- life 
 Table 3 compares scores reflecting physical signs, social activities, mood 
changes, and use of medical resources, between the three groups. There was 
a highly significant difference in QoL status between the thyroid hormone 
withdrawal groups (Groups I and II) and the rhTSH injection group (Group 
III). However, there was no difference in QoL during preparation for RI 
between patients in Groups I and II. 
 
- 17 - 
 
Table 3. Comparison of QoL scores between Groups. 
 
  Group I  Group II  Group III     p-value 
Symptoms and signs(0-4)   
  2.9±0.7  3.0±0.7  0.7±0.4   <0.001 
Duration of symptoms (0-3)      
1.8±1.2  1.9±1.0  0.2±0.1   <0.001 
Daily life (0-3)    
1.3 ±0.7  1.1±1.0  0.1±0.0     0.002 
Social life (0-3)    
2.1±1.1    2.0±0.9  0.1±0.0   <0.001 
Mood change and cognitive dysfunction (0-9) 
  3.5±1.9  3.7±1.7  1.8±0.9   0.004 
Genital symptoms (0-3)   
1.8±1.0  1.5±1.1  0.8±0.3   0.015 
Medical resource utilization (0-6)  
1.5±0.4  1.9±0.8  0.7±0.5   0.453 
Total (0-31)  
  15.1±3.1  15.8±4.1  4.2±1.9   <0.001 
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 IV. DISCUSSION 
 
DTC is on the increase worldwide, although the figures may reflect 
enhanced detection of small incidentalomas rather than an actual increase in 
DTC levels 
16,17
. Although proper management of small-sized DTC remains 
controversial, there is general agreement that total thyroidectomy and/or 
thyroid remnant ablation using RI are required. The optimal RI dose 
necessary for successful ablation in patients with low-risk DTC remains 
contentious. Some authors have employed dosimetric and kinetic 
methodology to define effective ablative doses, but most centers prefer to 
administer standard doses, varying with institutional preferences 
10,18,19
. 
Generally, the larger the dose the better the remnant ablation. However, 
higher activity of radioiodine was associated with more nausea and taste 
disturbances, and a longer stay in a radioprotected isolation unit. Some 
studies have shown that a standard dose of 30 mCi may be effective in low-
risk DTC patients 
20,21
. The present work showed that a RI dose of 30 mCi 
ablated most, if not all, thyroid remnants, in patients prepared either by 
thyroid hormone withdrawal or rhTSH injection. 
Remnant thyroid follicles can trap iodine and synthesize Tg, offering 
assistance in postoperative management of DTC. RI trapping and retention 
allows ablation of remnant thyroid tissue, and affords improved scan 
sensitivity for residual tissue detection postoperatively. RI ablation is 
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performed after thyroid hormone withdrawal, which increases endogenous 
TSH release to enhance, in turn, RI uptake by remnant tissue. Furthermore, 
serum Tg measurement after TSH stimulation is useful both to estimate 
ablation success and to detect recurrent disease 
11,22
. Hormone withdrawal 
for TSH stimulation is associated with negative physiological impacts on 
QoL 
1,23
. The use of rhTSH is a promising alternative for RI ablation 
preparation in DTC patients. However, the efficacy of rhTSH when low-
dose (30 mCi) RI treatment is planned is still controversial.  
Indisputable advantages of rhTSH use in patient preparation for thyroid 
remnant ablation after total thyroidectomy are the improved QoL and the 
need for less whole body irradiation 
3,4,6-9
. Previous reports on rhTSH use to 
these ends found that the procedure was efficacious in most patients given 
high doses (over 100 mCi) of RI 
2,4,7-9
. However, few reports have addressed 
rhTSH use in patients receiving low-dose (30 mCi) RI. One pilot study 
suggested that rhTSH use was less effective than LT4 withdrawal when the 
RI dose was 30 mCi 
6
. However, several other reports have shown that 
rhTSH patient preparation in low-dose RI patients compared favorably with 
preparation using thyroid hormone withdrawal 
11-13
. Our results suggest that 
rhTSH use is at least as effective as thyroid hormone withdrawal in 
preparation of low-risk patients for 30 mCi RI treatment. Considering about 
interference of iodine during ablation, this study was designed that the short 
interuppion of LT4 and 2 weeks iodine restriction diet could decrease the 
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size of iodine pool and that stimulation of rhTSH in this condition allows a 
rate of ablation that is at least the same as in the hypothyroid state. To avoid, 
at least partially, iodine interference coming from T4 metabolism, we 
choosed the modified rhTSH injection protocol with a short staoppage of 
LT4 from the day before rhTSH until iodine administration 
11
. In fact, 
urinary iodine excretion could measure stable iodine intake before RI 
treatment. Our study also shows that median urinary iodine levels were 
below the conventional 20 g/dL threshold in all study patients and showed 
no significant between-group differences. 
RI uptake (24-hour values) tended to be lower (1.8±1.6%) after rhTSH 
preparation than in the LT4 withdrawal Group (2.2±1.4%) or the LT3 
withdrawal Group (3.1±2.5%), although the differences were not 
statistically significant. If RI treatment is not delayed, we suggest that RI 
uptake is comparable in patients prepared either by rhTSH administration or 
LT4/T3 withdrawal. The 12-month follow-up scans assessing ablation were 
performed after LT4 withdrawal, based on previous evidence that 
postablation RI scan and follow-up neck US data were not significantly 
different between the three groups. In the absence of circulating anti-TgAbs, 
TSH-stimulated serum Tg level is certainly the most sensitive marker of 
residual thyroid tissue, indicating incomplete ablation 
24,25
. Consequently, 
we considered that TSH-stimulated serum Tg levels of less than 1 ng/mL at 
12 months postoperatively indicated successful ablation. By this measure, 
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the successful ablation rates did not differ significantly between the three 
groups (p=0.2061). Indeed, serum Tg measurement under TSH stimulation 
combined with neck US examination has been reported by several research 
groups to be the best indicator of complete remission in follow-up after 
initial treatment 
24,25
. 
The biokinetics of thyroid remnant RI ablation are both important and 
controversial 
23,26,27
. When rhTSH is used to prepare patients for RI 
treatment, biokinetics are complex and depend on the amount of RI taken up 
and stored in thyroid cells. A detailed theoretical and methodological study 
is beyond the scope of this paper. However, additional studies on the 
kinetics and dosimetry of RI treatment are required to understand both RI 
uptake and clearance. An unresolved issue in the present work is whether 
patient preparation using rhTSH impacts on long-term outcomes, compared 
with thyroid hormone withdrawal. This question can be answered only by 
patient follow-up in future years.  
Recently, the well-being of DTC patients has assumed greater importance, 
and several studies have reported impaired QoL associated with RI 
1-3,6,23
. It 
is important to reduce both the duration and extent of hypothyroidism 
caused by LT4 withdrawal. The use of rhTSH has greatly assisted in 
avoiding hypothyroidism. Another alternative, used empirically, is 
substitution of LT4 withdrawal by temporary cessation of LT3 therapy. LT3 
has a shorter half-life than LT4 and may be withdrawn for a shorter period 
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of time. Even though LT3 withdrawal should reduce hypothyroidism 
duration, this has never been clearly established. Few reports have addressed 
the topic. Leboeuf (2007) first explored QoL after LT3 withdrawal, 
compared with conventional LT4 withdrawal 
28
, and found (perhaps 
unexpectedly) that patients receiving additional LT3 after LT4 withdrawal 
showed a rate of hypothyroidism similar to that of patients in whom LT4 
was withdrawn 
28
. The cited authors sought to explain the data by claiming 
that thyroid hormone levels in the brain are controlled mainly by local 
transformation of T4 to T3, with little contribution from exogenous T3 
29
. 
Another explanation was that thyroid hormone receptors were not evenly 
distributed across all areas of the central nervous system, causing thyroid 
hormone effects to be variable in different brain regions 
30
. This might 
explain why we found no differences in hypothyroidism status between 
Group I and II. As expected, the symptoms and signs of hypothyroidism, 
and subjective QoL perceptions, were significantly better in rhTSH patients 
than in the thyroid hormone withdrawal groups. However, we also found 
that LT3 substitution after LT4 withdrawal in DTC patients did not prevent 
development of profound hypothyroidism, as measured by a modified 
Korean QoL questionnaire. 
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V. CONCLUSION 
 
rhTSH safely and effectively stimulated RI uptake by thyroid remnants in 
low-risk DTC patients, and was associated with clear clinical benefits in a 
substantial proportion of patients.  
In patients with low-risk DTC, the use of rhTSH prior to post-surgical 
thyroid remnant ablation with 30 mCi RI appears to represent the best 
treatment option. LT3 substitution after LT4 withdrawal did not prevent 
development of profound hypothyroidism 
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Appendix 1. Modified Pilot Questions for Determining Effects of 
Hypothyroidism (English version) 
1) Hypothyroidism symptoms and signs 
: Which types of symptoms disturbed you during the preparation period (Choose all 
that apply)? 
Fatigue (  ):0.5 
Weight gain (  ): 0.5 
Edema of extremities (  ):0.5 
Facial edema (  ):0.5 
Insomnia (  ):0.5 
Dry skin (  ):0.5 
Bowel habit change (  ):0.5 
Cold intolerance (  ):0.5 
  Total (  ) (0 – 4) 
2) Duration of symptoms  
: For how long did you experience symptoms? 
  Never (0) 
Less than 1 week (1) 
  1-2 weeks (2) 
  More than 2 weeks (3) 
Total (  ) (0 – 3) 
3) Daily life  
: During the preparation for RI treatment, were there any restrictions on your daily 
life, or were you unable to perform your daily activities as usual? 
Never (0) 
At intervals (1) 
Sometimes (2) 
Always (3) 
Total (  ) (0 – 3) 
4) Social life 
: During the preparation for 131RI treatment, did you have any problems in your 
social life or at work? 
- 31 - 
 
Never (0) 
At intervals (1) 
Sometimes (2) 
Always (3) 
Total (  ) (0 – 3) 
5) Mood changes & cognitive dysfunction 
: During the preparation for 131RI treatment, have you experienced any of the 
following feelings? 
5-1) Depression  
 (Gloomy attitude, pessimism about the future, feeling of sadness, tendency to 
weep, low morale misery, discouragement, hopelessness, emptiness, unhappiness, 
distress, pessimism) 
Never (0) 
At intervals (1) 
Sometimes (2) 
Always (3) 
5-2) Anxiety 
 (Subjective tension and irritability, loss of concentration, worrying about minor 
matters, apprehension, fears expressed without questioning, feelings of panic, 
feeling jumpy) 
Never (0) 
At intervals (1) 
Sometimes (2) 
Always (3) 
5-3) Retardation 
 (slowness of thought or speech, impaired concentration, decreased motor activity) 
Never (0) 
At intervals (1) 
Sometimes (2) 
Always (3) 
  
Total (  ) (0 – 9) 
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6) Genital symptoms 
 (loss of libido, impaired sexual performance, menstrual disturbances) 
Not at all (0) 
One or two times (1) 
Less than one week (2) 
More than one week (3) 
Total (  ) (0 – 3) 
 
7) Medical resource utilization 
7-1): During the preparation for 131RI treatment, did you consult your physician 
about related  
symptoms? 
Not at all (0) 
One time (1) 
More than two times (2) 
7-2): During the preparation for 131RI treatment, were you treated in a hospital for 
relief of your symptoms? 
Not at all (0) 
One time (1) 
More than two times (2) 
7-3): During the preparation for 131RI treatment, did you take additional 
medications? 
No (0) 
Yes (1) 
7-4): Did you have to be accompanied to the hospital? 
Not necessary (0) 
Necessary (1) 
 
Total (  ) (0 –6) 
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< ABSTRACT(IN KOREAN)> 
분화 갑상선암 환자에서 수술후 방사성 요오드 치료의 
전처치 방법에 대한 비교: 기존의 갑상선 호르몬(LT4/T3) 
중단요법 및 재조합 인간 갑상선 자극호르몬(rhTSH)주사법의 
효과 및 삶의 질에 미치는 영향에 대한 비교  
 
<지도교수  정웅윤 > 
 
연세대학교 대학원 의학과 
 
이잔디 
 
배경: 분화 갑상선암 환자에서 수술후 저용량(30mCi) 방사성 
요오드 치료를 사용하는 경우 전처치방법에서 재조합 인간 갑상선 
갑상선 자극호르몬(rhTSH) 사용시의 효과에 대한 연구는 많지 
않다. 본 연구의 목적은 국내에서 널리 사용되는 저용량 방사성 
요오드 치료시 전처치 방법으로 rhTSH 가 기존의 갑상선 호르몬 
억제요법(LT4/T3 withdrawal)과 동일한 효과를 보이는 지 또한 삶의 
질에 미치는 영향에 대해 비교하고자 하였다.  
방법: 2006년 2월부터 2007년 3월까지 본원에서 분화 갑상선암 
진단하에 갑상선 전절제술 및 중앙 구획 림프절 청소술후 저용량 
방사성 요오드 치료 예정 환자 291예를 대상으로 무작위 전향적 
연구를 시행하였다. 대상군을 방사성 요오드 치료의 전처치 
방법에 따라 고식적인 LT4의 4주 중단법(group I)(ㅜ=89), LT3로 
전환후 2주 중단법(group II)(ㅜ=133), 및 rhTSH 주사법(group 
III)(n=69)의 세군으로 분류하였고, 각각 전처치 방법의 효과를 
비교 하였다. 도한, 방사성 요오드 치료직전 환자의 감정상태 및 
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삶의 질 정도를 평가 하였다.  
결과: 세군 환자 모두 조직병리 검사 결과상 TNM 병기의 차이는 
없었다. 전처치후 TSH의 상승은 세군 모두 양호한 결과(평균 
82.24±18.21)를 보였으며, 세군간에 의미있는 차이는 
없었다(p=0.5213). 방사성 요오드 치료후 12개월후 시행한 방사성 
요오드 스캔, 경부 초음파 검사 및 TSH 자극후 thyroglobulin(Tg) 
수치로 방사성 요오드 치료의 효과를 판단한 결과 세군간에 
치료효과의 차이는 없었다(p=0.2061) . 삶의 질은 group III가 group I 
및 group II에 비해 휠씬 양호한 결과를 보였으나(p<0.0001), group 
I과 group II는 의미있는 차이를 보이지 않았다. 
결론:  본연구에서는 분화 갑상선암 환자에서 저용량 방사성 
요오드 치료(30mCI)의 전처치방법중 rhTSH 주입법이 기존의 
갑상선호르몬(LT4/LT3) 중단법과 동일한 유용성을 보인다는 것이 
증명되었다. 그러나, rhTSH 주사법이 기존의 갑상선 호르몬 
중단법에 비해 삶의 질 향상에 양호한 결과를 보이는 반면,  
LT3를 이용하여 갑상선 호르몬 중단기간을 줄이는 방법은 삶의 
질에 영향을 미치지 못하였다.  
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핵심되는 말 : 재조합 인간 갑상선 자극호르몬, 저용량 방사
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